Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 28;521(7553):489-94.
doi: 10.1038/nature14410.

Whole-genome characterization of chemoresistant ovarian cancer

Ann-Marie Patch  1 Elizabeth L Christie  2 Dariush Etemadmoghadam  3 Dale W Garsed  2 Joshy George  4 Sian Fereday  2 Katia Nones  1 Prue Cowin  2 Kathryn Alsop  2 Peter J Bailey  5 Karin S Kassahn  6 Felicity Newell  7 Michael C J Quinn  1 Stephen Kazakoff  1 Kelly Quek  7 Charlotte Wilhelm-Benartzi  8 Ed Curry  8 Huei San Leong  2 Australian Ovarian Cancer Study GroupAnne Hamilton  9 Linda Mileshkin  10 George Au-Yeung  2 Catherine Kennedy  11 Jillian Hung  11 Yoke-Eng Chiew  11 Paul Harnett  12 Michael Friedlander  13 Michael Quinn  14 Jan Pyman  14 Stephen Cordner  15 Patricia O'Brien  15 Jodie Leditschke  15 Greg Young  15 Kate Strachan  15 Paul Waring  16 Walid Azar  2 Chris Mitchell  2 Nadia Traficante  2 Joy Hendley  2 Heather Thorne  2 Mark Shackleton  10 David K Miller  7 Gisela Mir Arnau  2 Richard W Tothill  10 Timothy P Holloway  2 Timothy Semple  2 Ivon Harliwong  7 Craig Nourse  7 Ehsan Nourbakhsh  7 Suzanne Manning  7 Senel Idrisoglu  7 Timothy J C Bruxner  7 Angelika N Christ  7 Barsha Poudel  7 Oliver Holmes  1 Matthew Anderson  7 Conrad Leonard  1 Andrew Lonie  17 Nathan Hall  18 Scott Wood  1 Darrin F Taylor  7 Qinying Xu  1 J Lynn Fink  7 Nick Waddell  7 Ronny Drapkin  19 Euan Stronach  8 Hani Gabra  8 Robert Brown  8 Andrea Jewell  20 Shivashankar H Nagaraj  7 Emma Markham  7 Peter J Wilson  7 Jason Ellul  2 Orla McNally  11 Maria A Doyle  2 Ravikiran Vedururu  2 Collin Stewart  21 Ernst Lengyel  20 John V Pearson  1 Nicola Waddell  1 Anna deFazio  11 Sean M Grimmond  5 David D L Bowtell  22
Collaborators, Affiliations

Whole-genome characterization of chemoresistant ovarian cancer

Ann-Marie Patch et al. Nature. .

Erratum in

  • Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
    Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group; Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Patch AM, et al. Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. Nature. 2015. PMID: 26503049 No abstract available.

Abstract

Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Cancer Res. 2013 Jul 1;19(13):3474-84 - PubMed
    1. J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 - PubMed
    1. Clin Cancer Res. 2010 Apr 15;16(8):2344-51 - PubMed
    1. Cancer Res. 2012 Nov 1;72(21):5454-62 - PubMed
    1. J Clin Oncol. 2011 Aug 1;29(22):3008-15 - PubMed

Publication types

MeSH terms

Associated data